This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Consumer Sentiment Weakens: ETFs That Are Worth a Look
by Yashwardhan Jain
Rising oil prices and Middle East tensions are squeezing household finances and weakening consumer sentiment, steering investors toward defensive ETFs.
Stagflation Scare? ETFs May Help Protect Your Portfolio
by Yashwardhan Jain
Are stagflation risks returning as oil-driven inflation rises amid Middle East tensions? Here's how ETFs can help defend portfolios.
Middle East Turmoil and U.S. Debt Surge: ETFs in Focus
by Yashwardhan Jain
With U.S. budget deficits and already elevated debt, the ongoing Middle East war could worsen the fiscal outlook, making defensive ETF strategies worth considering for stability.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
ETFs to Play as Investors Chase Diversification Amid Tech Rout
by Yashwardhan Jain
From "software-mageddon" to rising AI capex pressuring Big Tech, diversification via defensive and global ETFs gains focus.
Healthcare ETFs in Focus as UnitedHealth Rises 4% Post Mixed Q4 Results
by Aparajita Dutta
Healthcare ETFs draw attention as UNH climbs 4% on mixed Q4 results, a better 2026 cost outlook, and rising concerns over Medicaid pressure.
Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China
by Aparajita Dutta
Novo Nordisk cuts Wegovy prices in China, which may shift investor focus toward diversified healthcare ETFs.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Healthcare ETF (IYH) Hits New 52-Week High
by Zacks Equity Research
IYH hits a 52-week high as healthcare gains momentum, lifted by sector strength and rising investor interest in safety and AI-driven tailwinds.
UnitedHealth Lifts EPS Outlook Despite Mixed Q3 Results: ETFs in Focus
by Aparajita Dutta
UNH posts mixed Q3 results with a revenue miss but lifts its 2025 EPS outlook, boosting interest in healthcare ETFs like IHF and XLV.